Analysis
Scribe Therapeutics priced an upsized initial public offering at $15 per share, the top of its range, raising $128.7 million -- well above its original $96 million target -- and shares surged as much as 67% in early Nasdaq trading under the ticker SCTX. The strong reception is notable because 2026's biotech IPO market has overwhelmingly rewarded later-stage, de-risked companies with existing clinical data, making Scribe's early-stage gene-editing listing a genuine exception.
The company's lead program, STX-1150, uses its proprietary ELXR epigenetic editing platform to silence the PCSK9 gene and lower LDL cholesterol -- without permanently altering the underlying DNA sequence, a meaningful distinction from earlier-generation gene-editing approaches that make irreversible cuts. Initial clinical data for the program is expected in the first half of 2027. Two additional preclinical programs, STX-1200 (targeting the LPA gene to reduce Lp(a) cholesterol) and STX-1400 (targeting APOC3 to regulate triglyceride metabolism), are partially funded by up to $25.7 million in grant support from the California Institute for Regenerative Medicine.
“Initial clinical data for the program is expected in the first half of 2027.”
Scribe's approach sits in a competitive field that includes larger, more established gene-editing players, but its epigenetic, non-permanent editing mechanism is a differentiated technical bet relative to companies making permanent DNA cuts -- a potentially important distinction for regulators and patients wary of irreversible genetic changes, even in a still-nascent field where long-term safety data across any editing approach remains limited.
Scribe plans to spend $30 million to $35 million continuing Phase 1 development of STX-1150, with $15 million to $20 million allocated to each of its two preclinical programs as they advance toward human testing -- a disclosed, program-by-program capital allocation plan that gives investors an unusually clear view of exactly what the IPO proceeds will fund.
What to watch: whether Scribe's 67% debut pop holds up over its first weeks of trading rather than fading the way many hot biotech debuts have this year, initial safety and tolerability data from the STX-1150 Phase 1 trial, and whether the strong reception encourages other early-stage gene-editing biotechs to test public markets rather than staying private longer.
